LevitasBio Completes Series C Financing

LevitasBio, Inc., www.levitasbio.com, a premier end-to-end pattern processing and evaluation supplier to the life sciences market, introduced it has accomplished Series C spherical financing of $35 million to advance its mission of offering highly effective, industry-leading strategies of mobile evaluation.

The funding permits LevitasBio to speed up its business success via the event of subsequent era high-throughput devices for pattern processing and evaluation. For the primary time ever, researchers utilizing LevitasBio’s groundbreaking expertise can study, analyze and perceive true organic signatures with out altering, stressing, or damaging cells—all whereas preserving the unique samples.

This new spherical of funding was led by Novalis Lifesciences with the participation of Pavilion Capital—a unit of Temasek Holdings Pte, an industry-leading strategic investor, and was supported by current investor Decheng Capital.

“This funding furthers our plans to become the benchmark platform for sample processing workflows,” said Joe Walthers, LevitasBio VP of Finance. “Our existing life sciences and pharmaceutical development clients overwhelmingly validated the power and success of our technology.”

“Novalis is excited to support LevitasBio as it transforms sample processing and analysis. This critical part of the workflow has stymied industry innovation and is underappreciated by the investment community,” said Paul Meister, Partner at Novalis LifeSciences. “We are impressed with LevitasBio’s distinctive options which have been commercialized to date and, with our funding, will allow their revolutionary development of pattern preparation and evaluation that powers life science analysis.”

Over the final yr LevitasBio expanded its spectacular portfolio with a number of product developments:

• LeviPrep—novel and empowering chilly tissue dissociation kits
• LeviSelect—particular floor marker enrichment assays
• LeviCell EOS System—subsequent era pattern processing platform with larger throughput and temperature management
• LeviMetrics—built-in evaluation software program for real-time on-platform evaluation

Martin Pieprzyk, CEO of LevitasBio, expounded that “Unlike current industry methods that induce alterations, stress or damage that mask the true biology of your sample, LevitasBio solutions preserve the key biological signatures that deliver the most viable and unaltered cells, providing researchers clearer data for actionable insights. I believe LevitasBio is expertly positioned to become the de facto industry standard for cellular analysis.”

LevitasBio—True Biology Begins Here

Our mission is to advance science and human well being by offering researchers with new and highly effective strategies of mobile evaluation. LevitasBio delivers the primary actually novel strategy to mobile evaluation in 30 years. Our proprietary label-free levitation expertise allows researchers to rescue and obtain larger high quality and amount of cells with out introducing bias, excessive stress, or modifications to gene expression profiles, making certain the integrity of downstream knowledge and evaluation is maintained.

About Novalis LifeSciences LLC

Novalis LifeSciences is an funding and advisory agency for the Life Science {industry} that was based in 2017 by Marijn E. Dekkers. With a workforce of skilled working executives from the Life Science {industry}, Novalis funds and advises visionary Life Science entrepreneurs. In addition to creating monetary investments, Novalis gives strategic and operational recommendation to portfolio firms which are at a crucial progress stage of their improvement. The agency has roughly $500M in property below administration in two funding funds.

www.novalislifesciences.com

View supply model on businesswire.com: https://www.businesswire.com/news/home/20221107005087/en/